ProfileGDS5678 / 1458800_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 64% 64% 62% 64% 66% 66% 63% 63% 63% 64% 63% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.929865
GSM967853U87-EV human glioblastoma xenograft - Control 23.812164
GSM967854U87-EV human glioblastoma xenograft - Control 33.8163464
GSM967855U87-EV human glioblastoma xenograft - Control 43.6451462
GSM967856U87-EV human glioblastoma xenograft - Control 53.7984464
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0071666
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0307266
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7832463
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7703163
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7458263
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8011764
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.754663
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8633164
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.806464